SkyLabs has entered the general subscription process for its listing on the KOSDAQ market. The initial public offering price has been set at 10,000 won, with the general subscription taking place over two days from June 26 to 27. Korea Investment & Securities is the lead underwriter.

SkyLabs operates a digital healthcare business based on ring-type wearable medical devices, enabling continuous measurement and management of patients' vital signs outside hospitals. Given the nature of this business, attention is focused on whether the subscription will succeed.

▶ Early Competition Ratio 'Low'… Final Results May Change

As of early tally on June 26, the proportional allocation competition ratio stood at 0.18 to 1, with the overall subscription competition ratio at 0.09 to 1. The number of subscription applications was counted at 598. However, as the subscription continues through June 27, the final competition ratio and application count could change significantly.

The company previously conducted demand forecasting for institutional investors from June 14 to 21.

▶ 24-Hour Blood Pressure Monitoring with Just a Ring, No Cuff

SkyLabs is a medical device manufacturer developing wearable medical devices and data platforms that allow vital signs of patients with chronic diseases to be continuously measured, analyzed, and transmitted outside hospitals. Its main business direction is to reduce gaps in patient monitoring that can occur under existing hospital-centered care and to build an environment for continuous health management.

Its flagship product is a ring-shaped, cuffless 24-hour blood pressure monitoring medical device. Rather than wrapping a cuff around the arm like conventional blood pressure monitors, it is designed to measure blood pressure changes using a PPG (photoplethysmography) sensor and its own algorithm. The measured data is automatically transmitted to the cloud, allowing medical staff to continuously check patients' blood pressure changes and conditions. Unlike existing measurement methods that capture blood pressure at a single point in time, a key feature is the ability to obtain blood pressure data over extended periods.

▶ Listing Schedule and Future Checkpoints

SkyLabs filed for a preliminary listing review on January 30 this year, received approval on June 24, and submitted its securities registration statement on July 7. After institutional demand forecasting, it fixed the offer price at 10,000 won and entered the general investor subscription stage.

The market expects the final competition ratio of the general subscription, deposit amounts, the level of institutional investors' lock-up commitments, and the volume of shares available for circulation after listing to be key variables. Along with the growth potential of the wearable medical device market, the expansion of SkyLabs' product commercialization, the pace of adoption by medical institutions, and domestic and international regulatory approvals and revenue growth are also cited as core factors for judging the company's mid- to long-term value.

[Please note that IPO stocks may trade below the offer price after listing or show large price fluctuations in the short term. Subscription competition ratios may continue to change during the subscription process, and it is difficult to judge future stock price movements based solely on high or low competition ratios. Please carefully make investment decisions after comprehensively reviewing the company's business competitiveness and performance, plans for using IPO proceeds, lock-up commitments, and the volume of shares available for circulation immediately after listing. This article is not intended to recommend subscription, purchase, or sale of any specific stock or to guarantee investment returns. This article was written with AI assistance.]